

#3  
DT  
10-2401

PATENT

Docket No. 2026-4202 US3

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

11011 U.S. PTB  
09/931700  
08/16/01

Applicant(s) : Frank CUTTITTA et al.

Group: TBA

Serial No : 09/011,922

Examiner: TBA

Filed : February 17, 1998

For : **FUNCTIONAL ROLE OF ADRENOMEDULLIN (AM) AND THE GENE-RELATED PRODUCT (PAMP) IN HUMAN PATHOLOGY AND PHYSIOLOGY**

**INFORMATION DISCLOSURE STATEMENT**

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application.

The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:  
  
\_\_\_\_\_  
  
\_\_\_\_\_
2. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. \_\_\_\_\_, filed \_\_\_\_\_.

4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:
- ☐ 37 C.F.R. §1.97(b)(1), within three months of the filing date of the above-identified application for filing date of the continued prosecution application filed on \_\_\_\_\_; or
  - ☐ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
  - ☒ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office Action on the merits, whichever event occurred last.
5. ☐ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6. ☐ A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
- ☐ A check in the amount of \$240.00 is enclosed in payment of the fee.
  - ☐ Charge the fee to Deposit Account No. 13-4500. Order No. \_\_\_\_\_. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7. ☐ A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
- a. ☐ one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
  - b. ☐ the attached petition requesting consideration of this Information Disclosure Statement; and
  - c. ☐ the fee due under 37 C.F.R. §1.17(i)(1) which is paid as set forth in paragraph 10 below.
8. ☐ A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with:
- a. ☐ 37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue;
  - b. ☐ 37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To withdraw Application From Issue.
  - c. ☐ The fee due under 37 C.F.R. §1.17(i)(1) is paid as set forth in paragraph 10 below.

9. ☐ I hereby certify that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

☐ I hereby certify that no item of information in the Information Disclosure Statement field herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after make reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

10. ☐ A check in the amount of \$130.00 is enclosed in payment of the fee due under C.F.R. §1.17(i)(1).

☐ Charge the fee due under C.F.R. §1.17(i)(1) to Deposit Account No. 13-4500. Order No. \_\_\_\_\_ A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

☒ The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500. Order No. 2026-4202 US3. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: October 21, 1998

By: Leslie A. Serunian  
Leslie A. Serunian  
Registration No. 35,353

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800  
(212) 751-6849 Facsimile

FORM: IDS.NY  
Rev. 05/26/98

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2026-4202 US3		SERIAL NO. 09/011,922	
<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)				APPLICANT Frank CUTTITTA et al.			
				FILING DATE February 17, 1998		GROUP ART UNIT To Be Assigned	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
		0 622 458 A2	11/2/94	Europe			
		WO 94/25482	11/10/94	PCT			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)</b>							
		K. Kitamura et al., "Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma," Biochem. Biophys. Res. Commun., 192[2]:553-560, 1993.					
		S., Sugo et al., "Production and secretion of adrenomedullin from vascular smooth muscle cells: Augmented production by tumor necrosis factor- $\alpha$ ." Biochem. Biophys. Res. Commun., 203[1]:719-726, 1994.					
		H. Kanazawa et al., "Adrenomedullin, a newly discovered hypotensive peptide, is a potent bronchodilator." Biochem. Biophys. Res. Commun., 205[1]:251-254, 1994.					
		T. Yamaguchi et al., "Effect of adrenomedullin on aldosterone secretion by dispersed rat adrenal zona glomerulosa cells." Life. Sci., 56[6]:379-387, 1995.					
		S. Sugo et al., "Interleukin-1, tumor-necrosis-factor and lipopolysaccharides additively stimulates production of adrenomedullin in vascular smooth muscle cells." Biochem. Biophys. Res. Commun., 207[1]:25-32, 1995.					
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

EL 853 256 591 US

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 2026-4202 US3		SERIAL NO. 09/011,922	
<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)					APPLICANT Frank CUTTITTA et al.			
					FILING DATE February 17, 1998		GROUP ART UNIT To Be Assigned	
<b>U.S. PATENT DOCUMENTS</b>								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)</b>								
			F. Satoh et al., "Adrenomedullin in human brain, adrenal-glands and tumor-tissues of pheochromocytoma, ganglioneuroblastoma and neuroblastoma." J. Clin. Endocrinol. Metabol., 80[5]:1750-1752, 1995.					
			H. Kamoi et al., "Adrenomedullin inhibits the secretion of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, from rat alveolar macrophages." Biochem. Biophys. Res. Commun., 211[3]:1031-1035, 1995.					
			E. Ahren et al., "Adrenomedullin is localized to the gut and stimulates insulin-secretion in the rat." Diabetologia 38:108A, 1995 (Abstract).					
			H. Michibata et al., "Production and action of adrenomedullin (AM) in cultured mesangial cells revealed by a specific monoclonal antibody to AM." J. Amer. Soc. Nephrol., 6:741, 1995 (Abstract #1856).					
			S. Kobayashi et al., "Adrenomedullin stimulates the cell cycle progression and the expression of c-fos messenger RNA in vascular smooth muscle cells in primary culture." Circulation, 92:I-694, 1995 (Abstract #3335).					
			A. Sato et al., "Adrenomedullin induces expression of c-fos and AP-1 activity in rat vascular smooth muscle cells and cardiomyocytes." Biochem. Biophys. Res. Commun., 217[1]:211-216, 1995.					
EXAMINER					DATE CONSIDERED			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2026-4202 US3		SERIAL NO. 09/011,922	
<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)				APPLICANT Frank CUTTITA et al.			
				FILING DATE February 17, 1998		GROUP ART UNIT To Be Assigned	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Papers, Etc.)</i>							
			T. Imai et al., "Hormonal regulation of rat adrenomedullin gene in vasculature." <i>Endocrinology</i> , 136[4]:1544-1548, 1995.				
			W.K. Samson et al., "A novel vasoactive peptide, adrenomedullin, inhibits pituitary adrenocorticotropin release." <i>Endocrinology</i> , 136[5]:2349-2352, 1995.				
			M.J. Miller et al., "Expression of adrenomedullin mRNA in normal human tissues and cancer cell lines as expressed by RT-PCR and immunoblot." <i>Proc. Amer. Assoc. Canc. Res.</i> , 36:261, 1995 (Abstract #1554).				
			A. Martinez et al., "Adrenomedullin, a new hypotensive peptide, is expressed in normal lung and in primary tumors." <i>Proc. Amer. Assoc. Canc. Res.</i> , 36:265, 1995 (Abstract #1580).				
			A. Martinez et al., "Expression of adrenomedullin in normal human lung and in primary tumors." <i>Endocrinology</i> 136[9]:4099-4105, 1995.				
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

EL 853 256 591 US

10000 900 007 US

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2026-4202 US3		SERIAL NO. 09/011,922	
<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)				APPLICANT Frank CUTTITTA et al.			
				FILING DATE February 17, 1998		GROUP ART UNIT To Be Assigned	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Papers, Etc.)</i>							
			G.D. Parkes et al., "ACTH-suppressive and vasodilator actions of adrenomedullin in conscious sheep." Journal of Neuroendocrinology (J. Neuroendo.), 7:923-929, 1995.				
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

EL 853 256 591 US

15 008 950 00 / US